N B Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 25-07-2024
- Paid Up Capital ₹ 2.00 M
as on 25-07-2024
- Company Age 22 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.68 M
as on 25-07-2024
- Satisfied Charges ₹ 1.20 M
as on 25-07-2024
- Revenue -22.98%
(FY 2023)
- Profit -71.40%
(FY 2023)
- Ebitda -41.14%
(FY 2023)
- Net Worth 2.96%
(FY 2023)
- Total Assets 32.27%
(FY 2023)
About N B Pharma
The Company is engaged in the Metals And Minerals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹8.68 M. The company has closed loans amounting to ₹1.20 M, as per Ministry of Corporate Affairs (MCA) records.
Rishu Bansal and Ashok Kumar serve as directors at the Company.
- CIN/LLPIN
U24239HR2002PTC034813
- Company No.
034813
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jan 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Haryana, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does N B Pharma Private Limited offer?
N B Pharma Private Limited offers a wide range of products and services, including Cookware and Cooking Utensils, Kitchen Hot Plates, Cooking Pan, Dinnerware and Serving Utensils, Aluminum Utensils, Cookware, Cooking Utensil.
Who are the key members and board of directors at N B Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rishu Bansal  | Director | 14-Jan-2011 | Current |
| Ashok Kumar | Director | 19-Jan-2011 | Current |
Financial Performance of N B Pharma.
N B Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 22.98% decrease. The company also saw a substantial fall in profitability, with a 71.4% decrease in profit. The company's net worth moved up by a moderate rise of 2.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of N B Pharma?
In 2023, N B Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Jul 2020 | ₹0.68 M | Open |
Others Creation Date: 25 Mar 2019 | ₹3.00 M | Open |
Punjab National Bank Creation Date: 26 Mar 2012 | ₹2.00 M | Open |
How Many Employees Work at N B Pharma?
Unlock and access historical data on people associated with N B Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of N B Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped N B Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
